Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 2
2004 4
2005 5
2006 2
2007 1
2008 4
2009 4
2010 1
2014 1
2015 2
2016 2
2017 3
2018 1
2025 1
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

30 results

Results by year

Filters applied: . Clear all
Page 1
Ribavirin.
[No authors listed] [No authors listed] 2025 Aug 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. 2025 Aug 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. PMID: 29999673 Free Books & Documents. Review.
Peginterferon alfa-2a (40KD) (PEGASYS) plus ribavirin (COPEGUS) in retreatment of chronic hepatitis C patients, nonresponders and relapsers to previous conventional interferon plus ribavirin therapy.
Parise E, Cheinquer H, Crespo D, Meirelles A, Martinelli A, Sette H, Gallizi J, Silva R, Lacet C, Correa E, Cotrim H, Fonseca J, Paraná R, Spinelli V, Amorim W, Tatsch F, Pessoa M; Brazilian Pegasys Cooperative Study Group. Parise E, et al. Braz J Infect Dis. 2006 Feb;10(1):11-6. doi: 10.1590/s1413-86702006000100003. Epub 2006 Jun 2. Braz J Infect Dis. 2006. PMID: 16767309 Free article.
Hepatic steatosis in patients with chronic hepatitis C virus genotype 2 or 3 does not affect viral response in patients treated with peginterferon alpha-2a (40KD) (PEGASYS) plus ribavirin (COPEGUS) for 16 or 24 weeks.
Rodriguez-Torres M, Govindarajan S, Diago M, Morgan T, Anand B, Barange K, Suter F, Lin A, Hooper G, Shiffman M. Rodriguez-Torres M, et al. Liver Int. 2009 Feb;29(2):237-41. doi: 10.1111/j.1478-3231.2008.01859.x. Epub 2008 Aug 14. Liver Int. 2009. PMID: 18710427
Antiviral therapy in chronic hepatitis E: a systematic review.
Peters van Ton AM, Gevers TJ, Drenth JP. Peters van Ton AM, et al. J Viral Hepat. 2015 Dec;22(12):965-73. doi: 10.1111/jvh.12403. Epub 2015 Mar 11. J Viral Hepat. 2015. PMID: 25760481
The keywords '"Hepatitis E" or HEV' AND 'ribavirin or Rebetol or Copegus' OR 'pegylated interferon OR peginterferon' were combined. The primary outcome was sustained viral response (SVR). ...
The keywords '"Hepatitis E" or HEV' AND 'ribavirin or Rebetol or Copegus' OR 'pegylated interferon OR peginterferon' were combined. T …
Peginterferon-alpha-2a (40kD) plus ribavirin: a review of its use in hepatitis C Virus And HIV co-infection.
Plosker GL, Keating GM. Plosker GL, et al. Drugs. 2004;64(24):2823-43. doi: 10.2165/00003495-200464240-00009. Drugs. 2004. PMID: 15563253 Review.
Although the optimal anti-HCV regimen is not established in the more difficult-to-treat population with HIV-HCV co-infection, much of the data in this clinical setting have been derived from studies evaluating peginterferon-alpha-2a (40kD) [Pegasys] plus ribavirin (Copegus …
Although the optimal anti-HCV regimen is not established in the more difficult-to-treat population with HIV-HCV co-infection, much of the da …
Peginterferon-alpha-2a (40kD) plus ribavirin: a review of its use in the management of chronic hepatitis C.
Keating GM, Curran MP. Keating GM, et al. Drugs. 2003;63(7):701-30. doi: 10.2165/00003495-200363070-00008. Drugs. 2003. PMID: 12656650 Review.
Subsequently, combination therapy with peginterferon-alpha-2a (40kD) [Pegasys] and ribavirin (Copegus trade mark, Rebetol) was investigated to establish if the efficacy of peginterferon-alpha-2a (40kD) monotherapy could be further enhanced. ...
Subsequently, combination therapy with peginterferon-alpha-2a (40kD) [Pegasys] and ribavirin (Copegus trade mark, Rebetol) was invest …
Peginterferon-alpha 2a (40 kDa)/ribavirin combination for the treatment of chronic hepatitis C infection.
Vogel W. Vogel W. Expert Rev Anti Infect Ther. 2003 Oct;1(3):423-31. doi: 10.1586/14787210.1.3.423. Expert Rev Anti Infect Ther. 2003. PMID: 15482139 Review.
Treatment of this chronic viral infection has considerably improved with the introduction of ribavirin-interferon combination therapy. Ribavirin (Copegus, Rebetol) is a synthetic nucleoside analogue with broad antiviral effects. It is absorbed readily upon oral administrat …
Treatment of this chronic viral infection has considerably improved with the introduction of ribavirin-interferon combination therapy. Ribav …
30 results